AN UNBIASED VIEW OF BMS-199264 HYDROCHLORIDE

All enrolled sufferers who obtained a minimum of just one dose of zosuquidar or placebo for the duration of induction were being monitored for your event of adverse gatherings (439 people, 219 on zosuquidar and 210 on placebo). The most typical adverse activities have been connected to the period of prolonged and considerable myelosuppression as is